Table 1.

Dose-escalation scheme and the number of patients treated in each cohort

Cohort no.Dose (TCID50)Days of treatment per cycleNo. patients per cohortPatient nos.
11 × 10813RL01-RL03
21 × 10833RL04-RL06
31 × 10854RL07-RL10
43 × 10853RL11-RL13
51 × 10953RL14-RL16
63 × 10953RL17-RL19
71 × 101056RL20-RL25
83 × 101058RL26-RL33
  • NOTE: The duration of each treatment cycles was 4 wk. Patients are identified by study numbers RL01 to RL33 and their recruitment to individual dose cohorts is indicated. No attempt was made to escalate the dose beyond the 3 × 1010 dose level, because this was considered to be the manufacturing limit of the virus.